Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On January30, 2019, Momenta Pharmaceuticals,Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”), at which the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000.
The Company’s board of directors previously approved the amendment to the Certificate of Incorporation and, on January30, 2019, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware.
The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit3.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company held the Special Meeting on January30, 2019.Of the 98,470,296 shares of the Company’s common stock entitled to vote, 86,986,299 shares were present in person or by proxy at the Special Meeting.The matters voted on at the Special Meeting and the voting results for each matter were as follows:
1. The stockholders approved the amendment of the Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000.
|
For: |
86,080,378 |
|
Against: |
893,010 |
|
Abstain: |
12,911 |
|
Broker Non-Votes: |
2. The stockholders approved the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Special Meeting to approve the proposal to amend the Certificate of Incorporation.
|
For: |
76,167,201 |
|
Against: |
10,783,226 |
|
Abstain: |
35,872 |
|
Broker Non-Votes: |
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
MOMENTA PHARMACEUTICALS INC Exhibit
EX-3.1 2 a19-3767_1ex3d1.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MOMENTA PHARMACEUTICALS,…
To view the full exhibit click here
About Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.
